TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
GAITHERSBURG, Md., Dec. 29, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2017.
- 35th Annual J.P. Morgan Healthcare Conference
San Francisco, CA
January 9-12, 2017
Presentation: January 10, 2017
- Wells Fargo Specialty and Generic Drug Summit
Orlando, FL
February 13, 2017
Presentation time TBD - Cowen & Co. 37th Annual Health Care Conference
Boston, MA
March 6-8, 2017
Presentation day and time TBD
Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as this information becomes available.
For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
